We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Most cancer tissues showed moderate nuclear immunoreactivity. Few testis, pancreas and urothelial cancers displayed strong staining. Several cases of prostate, renal, endometrial, cervical cancers and hepatocellular carcinomas were weakly stained or negative.
Cancer tissues displayed moderate to strong nuclear positivity.
GENE INFORMATION
Gene name
ADAR (HGNC Symbol)
Synonyms
ADAR1, G1P1, IFI4
Description
Adenosine deaminase, RNA-specific (HGNC Symbol)
Entrez gene summary
This gene encodes the enzyme responsible for RNA editing by site-specific deamination of adenosines. This enzyme destabilizes double-stranded RNA through conversion of adenosine to inosine. Mutations in this gene have been associated with dyschromatosis symmetrica hereditaria. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2010]
Enzymes ENZYME proteins Hydrolases SPOCTOPUS predicted membrane proteins Predicted intracellular proteins Plasma proteins Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001649 [osteoblast differentiation] GO:0001701 [in utero embryonic development] GO:0002244 [hematopoietic progenitor cell differentiation] GO:0002566 [somatic diversification of immune receptors via somatic mutation] GO:0003677 [DNA binding] GO:0003723 [RNA binding] GO:0003726 [double-stranded RNA adenosine deaminase activity] GO:0004000 [adenosine deaminase activity] GO:0005515 [protein binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005730 [nucleolus] GO:0005737 [cytoplasm] GO:0006382 [adenosine to inosine editing] GO:0006396 [RNA processing] GO:0006397 [mRNA processing] GO:0006606 [protein import into nucleus] GO:0006611 [protein export from nucleus] GO:0009615 [response to virus] GO:0010467 [gene expression] GO:0016020 [membrane] GO:0016553 [base conversion or substitution editing] GO:0016556 [mRNA modification] GO:0019221 [cytokine-mediated signaling pathway] GO:0030218 [erythrocyte differentiation] GO:0031054 [pre-miRNA processing] GO:0035196 [production of miRNAs involved in gene silencing by miRNA] GO:0035280 [miRNA loading onto RISC involved in gene silencing by miRNA] GO:0035455 [response to interferon-alpha] GO:0043066 [negative regulation of apoptotic process] GO:0044387 [negative regulation of protein kinase activity by regulation of protein phosphorylation] GO:0044530 [supraspliceosomal complex] GO:0044822 [poly(A) RNA binding] GO:0045070 [positive regulation of viral genome replication] GO:0045071 [negative regulation of viral genome replication] GO:0045087 [innate immune response] GO:0046872 [metal ion binding] GO:0051607 [defense response to virus] GO:0060216 [definitive hemopoiesis] GO:0060337 [type I interferon signaling pathway] GO:0060339 [negative regulation of type I interferon-mediated signaling pathway] GO:0061484 [hematopoietic stem cell homeostasis] GO:0098586 [cellular response to virus] GO:1900369 [negative regulation of RNA interference]
Enzymes ENZYME proteins Hydrolases SPOCTOPUS predicted membrane proteins Predicted intracellular proteins Plasma proteins Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)